Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Angelo Di Leo

Showing results (31-40 of 187) with videos related to

Pageof 19
Sort By:
European Journal of Cancer (Oxford, England : 1990)|August 19, 2007
Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?Laura Biganzoli, Sara Licitra, Wederson Claudino, et al.
Cancer Treatment Reviews|September 18, 2009
The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patientsCatherine Oakman, Erica Moretti, Francesca Galardi, et al.
Cancers|November 28, 2013
Significance of micrometastases: circulating tumor cells and disseminated tumor cells in early breast cancerCatherine Oakman, Marta Pestrin, Silvia Bessi, et al.
Ecancermedicalscience|April 17, 2013
Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up?Giuseppe Curigliano, Carmen Criscitiello, Fabrice Andrè, et al.
Critical Reviews in Oncology/Hematology|February 24, 2007
Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: where do we stand?Laura Biganzoli, Wederson M Claudino, Marta Pestrin, et al.
BMC Medicine|April 11, 2015
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancersIlenia Migliaccio, Luca Malorni, Christopher D Hart, et al.
Breast (Edinburgh, Scotland)|September 1, 2015
Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypesChristopher D Hart, Giuseppina Sanna, Olimpia Siclari, et al.
Breast (Edinburgh, Scotland)|August 28, 2007
Using specific cytotoxics with a targeted mindAngelo Di Leo, Wederson M Claudino, Marta Pestrin, et al.
Cancers|December 5, 2019
The Emerging Role of <i>ESR1</i> Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine TherapyIrene De Santo, Amelia McCartney, Ilenia Migliaccio, et al.
Dermatology Online Journal|April 28, 2006
Generalized B-cell non Hodgkin's lymphoma in association with leukocytoclastic vasculitis and disseminated intravascular coagulationCarla Cardinali, Simone Santini, Angelo di Leo, et al.
Pageof 19

Showing results (31-40 of 187) with videos related to

Sort By:
Pageof 19
European Journal of Cancer (Oxford, England : 1990)|August 19, 2007
Clinical decision making in breast cancer: TAM and aromatase inhibitors for older patients -- a jungle?Laura Biganzoli, Sara Licitra, Wederson Claudino, et al.
Cancer Treatment Reviews|September 18, 2009
The role of topoisomerase IIalpha and HER-2 in predicting sensitivity to anthracyclines in breast cancer patientsCatherine Oakman, Erica Moretti, Francesca Galardi, et al.
Cancers|November 28, 2013
Significance of micrometastases: circulating tumor cells and disseminated tumor cells in early breast cancerCatherine Oakman, Marta Pestrin, Silvia Bessi, et al.
Ecancermedicalscience|April 17, 2013
Highlights from the 13th St Gallen International Breast Cancer Conference 2013. Access to innovation for patients with breast cancer: how to speed it up?Giuseppe Curigliano, Carmen Criscitiello, Fabrice Andrè, et al.
Critical Reviews in Oncology/Hematology|February 24, 2007
Selection of chemotherapeutic drugs in adjuvant programs based on molecular profiles: where do we stand?Laura Biganzoli, Wederson M Claudino, Marta Pestrin, et al.
BMC Medicine|April 11, 2015
Endocrine therapy considerations in postmenopausal patients with hormone receptor positive, human epidermal growth factor receptor type 2 negative advanced breast cancersIlenia Migliaccio, Luca Malorni, Christopher D Hart, et al.
Breast (Edinburgh, Scotland)|September 1, 2015
Defining optimal duration and predicting benefit from chemotherapy in patients with luminal-like subtypesChristopher D Hart, Giuseppina Sanna, Olimpia Siclari, et al.
Breast (Edinburgh, Scotland)|August 28, 2007
Using specific cytotoxics with a targeted mindAngelo Di Leo, Wederson M Claudino, Marta Pestrin, et al.
Cancers|December 5, 2019
The Emerging Role of <i>ESR1</i> Mutations in Luminal Breast Cancer as a Prognostic and Predictive Biomarker of Response to Endocrine TherapyIrene De Santo, Amelia McCartney, Ilenia Migliaccio, et al.
Dermatology Online Journal|April 28, 2006
Generalized B-cell non Hodgkin's lymphoma in association with leukocytoclastic vasculitis and disseminated intravascular coagulationCarla Cardinali, Simone Santini, Angelo di Leo, et al.
Pageof 19